Regeneron (REGN) Beats Estimates, Fueled by Covid Therapy and Eylea
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Regeneron (REGN) Results Highlight Strong Fundamentals, Focus Remains on Novel Product Readouts - BMO Capital
February 4, 2022 3:04 PM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $780.00 price target on Regeneron Pharma (NASDAQ: REGN), following the company's recent quarterly report.
The analyst quotes: "Key products continuing strong growth; all eyes to pipeline execution. FY2021 results highlighted the strong... More
Regeneron Pharma (REGN) PT Raised to $640 at Cowen
February 4, 2022 12:55 PM ESTCowen analyst Tyler Van Buren raised the price target on Regeneron Pharma (NASDAQ: REGN) to $640.00 (from $625.00) while maintaining a Market Perform rating following reuslts.
The analyst commented, "A strong commercial performance of the core business led to strong Q4 results. Understanding... More
